In traditional oncology, the "trial-and-error" method has long been a frustrating reality for patients. Clinicians prescribe standard chemotherapy and targeted regimens based on global guidelines.Today, a revolutionary technology known as Organoid Drug Sensitivity Testing is dismantling this paradigm. By cultivating a patient's micro-scale "biological avatar" in the laboratory, clinicians can pre-screen and predict the most effective drug combination before administration.

In the realm of advanced hepatobiliary oncology, a diagnosis of locally advanced, unresectable cholangiocarcinoma—especially with major vascular involvement—has historically been considered a clinical "dead end." However, a recent case from Sir Run Run Shaw Hospital (SRRSH) is challenging this status quo, demonstrating how a "Conversion Therapy" paradigm can successfully redefine treatment boundaries.